A trial of a new version of the AstraZeneca vaccine is to start at UCLH to see if it is effective against the Covid-19 variant first identified in South Africa.
A UCL report published today sets out a new framework and recommendations on how to reduce health inequities across the UK and ‘build back fairer’ following the pandemic.
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to research in which UCLH played a key role.
Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains.
UCLH and UCL are part of an international consortium awarded a substantial prize to further develop an innovative infectious disease outbreak detection system.
Presence of tumour DNA in the blood – a biomarker or indicator of disease first identified by a BRC-supported consortium – can predict which cancer patients are most likely to relapse after having a tumour surgically removed and most likely to benefit from immunotherapy.
More than nine in ten patients taking part in research at UCLH would consider doing so again and felt valued for their participation, according to a national survey.
Pioneering technology developed by UCL and Africa Health Research Institute (AHRI) could transform the ability to accurately interpret HIV test results.
UCLH is the first site in the UK to recruit to an international vaccine study looking at the safety, tolerability and immune response generated by the Pfizer-BioNTech Covid-19 vaccine in healthy pregnant women.
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
